These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6118669)

  • 1. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
    Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
    Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
    Poplack DG; Sallan SE; Rivera G; Holcenberg J; Murphy SB; Blatt J; Lipton JM; Venner P; Glaubiger DL; Ungerleider R; Johns D
    Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.
    Yamaguchi K; Yul LS; Oda T; Maeda Y; Ishii M; Fujita K; Kagiyama S; Nagai K; Suzuki H; Takatsuki K
    Leuk Res; 1986; 10(8):989-93. PubMed ID: 3489140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
    Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
    Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
    Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deoxycoformycin in the treatment of leukemias and lymphomas.
    Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
    Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic conversion of acute leukaemia from T-lymphoblastic to myeloblastic induced by therapy with 2'-deoxycoformycin.
    Murphy SB; Stass S; Kalwinsky D; Rivera G
    Br J Haematol; 1983 Oct; 55(2):285-93. PubMed ID: 6604543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane phenotype and response to deoxycoformycin in mature T cell malignancies.
    Dearden CE; Matutes E; Hoffbrand AV; Ganeshaguru K; Brozovic M; Williams HJ; Traub N; Mills M; Linch DC; Catovsky D
    Br Med J (Clin Res Ed); 1987 Oct; 295(6603):873-5. PubMed ID: 2890401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose deoxycoformycin in lymphoid malignancy.
    Grever MR; Leiby JM; Kraut EH; Wilson HE; Neidhart JA; Wall RL; Balcerzak SP
    J Clin Oncol; 1985 Sep; 3(9):1196-201. PubMed ID: 2993534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
    Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
    Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the biochemical sequelae of therapy in Thy-acute lymphoblastic leukaemia with the adenosine deaminase inhibitor 2' deoxycoformycin.
    Russell NH; Prentice HG; Lee N; Piga A; Ganeshaguru K; Smyth JF; Hoffbrand AV
    Br J Haematol; 1981 Sep; 49(1):1-9. PubMed ID: 6974003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia.
    Daenen S; Rojer RA; Smit JW; Halie MR; Nieweg HO
    Br J Haematol; 1984 Dec; 58(4):723-7. PubMed ID: 6097297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of hairy-cell leukaemia with 2'-deoxycoformycin.
    Johnston JB; Glazer RI; Pugh L; Israels LG
    Br J Haematol; 1986 Jul; 63(3):525-34. PubMed ID: 3488071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.
    Winick N; Buchanan GR; Murphy SB; Yu A; Boyett J
    Med Pediatr Oncol; 1988; 16(5):327-32. PubMed ID: 3263563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deoxycoformycin in therapy of refractory lymphoid neoplasms.
    Ho AD; Thaler J; Kuse R; Willemze R; Mandelli F; Lauria F; Zittoun R; Stryckmans P
    Onkologie; 1988 Feb; 11(1):35-7. PubMed ID: 3283623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma.
    Grever MR; Bisaccia E; Scarborough DA; Metz EN; Neidhart JA
    Blood; 1983 Feb; 61(2):279-82. PubMed ID: 6600401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of deoxycoformycin.
    Major PP; Agarwal RP; Kufe DW
    Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of pentostatin (2'-deoxycoformycin, dCF) in the management of lymphoproliferative malignancies.
    Spiers AS
    Blood Rev; 1987 Jun; 1(2):106-10. PubMed ID: 3332090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.